SCIENTIFIC PROGRAM

13:00 – 14:00 AF review
Moderators:
Dr. Mihal Tase, Dr. Enver Atalar
  AF prevalence, clinical significance, diagnosis, classification, burden, screening-monitoring
Dr. Huseyin Dursun
14:00 – 14:30 Coffee Break
14:30 – 15:30 Determination of stroke risk in AF
Moderators:
Dr. Alban Dibra, Dr. Ahmet Yildiz
  What is CHADS-VASC scoring system; is it sufficient?
Dr. Ahmet Yildiz
  How are risk factors other than CHADS-VASC scoring system important?
Dr. Alban Dibra
15:30 – 16:00 Coffee Break
16:00 – 17:00 DOACs – VKA in 2002; Is it applicable in NVAF?
Moderators:
Dr. Telat Keles, Dr. Mimoza Lezha
  How should an ideal DOAC
Dr. Telat Keles
  DOAK studies (Summary) RCT
Dr. Mimoza Lezha
09:30 – 10:30 OAC therapy in groups with NVAF
Moderators:
Dr. Enver Atalar
Panelists:
Dr. Baris Ayguc, Dr. Huseyin Dursun

  • Elder/Vulnerable patient
  • CKD
  • The patient with stroke history
  • The patient with hemorrhage history
10:30 – 11:00 Coffee Break
11:00 – 12:00 OAC therapy in groups with NVAF
Moderators:
Dr. Naltin Shuka, Dr. Telat Keles
Panelists: Dr. Naltin Shuka, Dr. Telat Keles, Dr. Enver Atalar

  • AKS/PKG patient
  • Patients with cardiac valve disease
  • Cancer patients
12:00 – 13:30 Lunch
13:30 – 14:30 AF rhythm and velocity control
Moderators:
Dr. Leonard Simoni, Dr. Baris Ayguc
Panelists: Dr. Naltin Shuka, Dr. Leonard Simoni, Dr. Baris Ayguc

  • Rhythm control or velocity control in AF?
  • Which antiarrhythmic drugs should be used in rhythm and rate control, what should be the target heart rate?
  • Therapies beyond OAC in AF
  • Ablation; when, to whom? Which method?
  • LAA closure indications
14:30 – 15:00 Coffee Break
15:00 – 16:00 OAC Therapy in NVAF with CASES
Moderators:
Dr. Mihal Tase, Dr. Enver Atalar
Panelists: Dr. Enver Atalar, Dr. Alban Dibra, Dr. Huseyin Dursun

  • Low risk patient
  • The patient with minor bleeding history
  • The patient with chronic kidney diseases
  • High risk patient